Karthik Selvaraju
Overview
Explore the profile of Karthik Selvaraju including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Cuesta E, Martinez P, Selvaraju K, Ulltjarn G, Gomez Pozo A, DAgostino G, et al.
Elife
. 2024 Sep;
13.
PMID: 39248648
CXCR4 is a ubiquitously expressed chemokine receptor that regulates leukocyte trafficking and arrest in both homeostatic and pathological states. It also participates in organogenesis, HIV-1 infection, and tumor development. Despite...
2.
Gubat J, Sjostrand L, Selvaraju K, Telli K, Darcy P
Sci Rep
. 2024 Jun;
14(1):13037.
PMID: 38844605
The proteasome-associated deubiquitinase USP14 is a potential drug target. Using an inducible USP14 knockout system in colon cancer cells, we found that USP14 depletion impedes cellular proliferation, induces cell cycle...
3.
Gubat J, Selvaraju K, Sjostrand L, Singh D, Turkina M, Schmierer B, et al.
Front Oncol
. 2022 May;
12:852980.
PMID: 35530310
Dienone compounds have been demonstrated to display tumor-selective anti-cancer activity independently of the mutational status of TP53. Previous studies have shown that cell death elicited by this class of compounds...
4.
Selvaraju K, Lotfi K, Gubat J, Miquel M, Nilsson A, Hill J, et al.
Biomolecules
. 2021 Sep;
11(9).
PMID: 34572552
Dienone compounds with a 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore have been widely reported to show tumor cell selectivity. These compounds target the ubiquitin-proteasome system (UPS), known to be essential for the viability of...
5.
Mofers A, Selvaraju K, Gubat J, Darcy P, Linder S
Eur J Pharmacol
. 2020 Nov;
889:173709.
PMID: 33166494
Inhibitors of the 20S proteasome such as bortezomib (Velcade) and carfilzomib (Kypriolis) are in clinical use for the treatment of patients with multiple myeloma and mantle cell lymphoma. In an...
6.
Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570
Pellegrini P, Selvaraju K, Faustini E, Mofers A, Zhang X, Ternerot J, et al.
Int J Mol Sci
. 2020 Jul;
21(13).
PMID: 32635430
The proteasome is a validated target of cancer therapeutics. Inhibition of proteasome activity results in the activation of the unfolded protein response (UPR) characterized by phosphorylation of eukaryotic initiation factor...
7.
Selvaraju K, Mofers A, Pellegrini P, Salomonsson J, Ahlner A, Morad V, et al.
Sci Rep
. 2019 Nov;
9(1):17501.
PMID: 31745183
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
8.
Mofers A, Perego P, Selvaraju K, Gatti L, Gullbo J, Linder S, et al.
PLoS One
. 2019 Oct;
14(10):e0223807.
PMID: 31639138
Background: b-AP15/VLX1570 are small molecule inhibitors of the ubiquitin specific peptidase 14 (USP14) and ubiquitin carboxyl-terminal hydrolase 5 (UCHL5) deubiquitinases (DUBs) of the 19S proteasome. b-AP15/VLX1570 have been shown to...
9.
Selvaraju K, Mofers A, Pellegrini P, Salomonsson J, Ahlner A, Morad V, et al.
Sci Rep
. 2019 Jul;
9(1):9841.
PMID: 31285509
A large number of natural products have been advocated as anticancer agents. Many of these compounds contain functional groups characterized by chemical reactivity. It is not clear whether distinct mechanisms...
10.
Zhang X, Selvaraju K, Saei A, Darcy P, Zubarev R, Arner E, et al.
Biochimie
. 2019 Apr;
162:46-54.
PMID: 30946948
Auranofin is a gold (I)-containing compound used for the treatment of rheumatic arthritis. Auranofin has anticancer activity in animal models and is approved for clinical trials for lung and ovarian...